Pharma-Bio Serv Inc
Pharma-Bio Serv, Inc. operates as a regulatory affair, compliance, and technology transfer services consulting firm in Puerto Rico, the United States, Europe, Brazil, and internationally. The company offers a broad range of technical compliance consulting services, including regulatory affairs, quality assurance, compliance, technology transfer, validation, engineering, project management, and pr… Read more
Pharma-Bio Serv Inc (PBSV) - Total Liabilities
Latest total liabilities as of October 2025: $1.74 Million USD
Based on the latest financial reports, Pharma-Bio Serv Inc (PBSV) has total liabilities worth $1.74 Million USD as of October 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Pharma-Bio Serv Inc - Total Liabilities Trend (2007–2025)
This chart illustrates how Pharma-Bio Serv Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Pharma-Bio Serv Inc Competitors by Total Liabilities
The table below lists competitors of Pharma-Bio Serv Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ilyda SA
AT:ILYDA
|
Greece | €1.78 Million |
|
New England Realty Associates LP
NYSE MKT:NEN
|
USA | $563.89 Million |
|
IVF_INSPIRE IVF
BK:IVF
|
Thailand | ฿84.37 Million |
|
NEP Realty and Industry Public Company Limited
BK:NEP
|
Thailand | ฿6.62 Million |
|
Kohinoor Foods Limited
NSE:KOHINOOR
|
India | ₹3.83 Billion |
|
Standard Industries Limited
NSE:SIL
|
India | ₹441.07 Million |
|
Healthy Choice Wellness Corp.
NYSE MKT:HCWC
|
USA | $27.82 Million |
|
Home Pottery Public Company Limited
BK:HPT
|
Thailand | ฿93.80 Million |
Liability Composition Analysis (2007–2025)
This chart breaks down Pharma-Bio Serv Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.70 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.15 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.13 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Pharma-Bio Serv Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Pharma-Bio Serv Inc (2007–2025)
The table below shows the annual total liabilities of Pharma-Bio Serv Inc from 2007 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-10-31 | $1.74 Million | -32.52% |
| 2024-10-31 | $2.58 Million | -31.74% |
| 2023-10-31 | $3.78 Million | -7.77% |
| 2022-10-31 | $4.09 Million | -18.25% |
| 2021-10-31 | $5.01 Million | -30.48% |
| 2020-10-31 | $7.20 Million | +19.53% |
| 2019-10-31 | $6.03 Million | +17.81% |
| 2018-10-31 | $5.11 Million | +219.12% |
| 2017-10-31 | $1.60 Million | -26.73% |
| 2016-10-31 | $2.19 Million | +0.54% |
| 2015-10-31 | $2.18 Million | -19.42% |
| 2014-10-31 | $2.70 Million | -16.45% |
| 2013-10-31 | $3.23 Million | +13.01% |
| 2012-10-31 | $2.86 Million | +9.33% |
| 2011-10-31 | $2.62 Million | +75.69% |
| 2010-10-31 | $1.49 Million | +9.57% |
| 2009-10-31 | $1.36 Million | -66.53% |
| 2008-10-31 | $4.06 Million | -45.11% |
| 2007-10-31 | $7.40 Million | -- |